OABI Stock Analysis: Buy, Sell, or Hold?
OABI - OmniAb, Inc. Common Stock
$2.00
0.04 (2.04%)
▲
5d:
+1.52%
30d:
-17.01%
90d:
+41.84%
HOLD
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When OABI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OABI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: OABI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: OABI is currently trading at $2.00, which is considered slightly low relative to its 30-day fair value range of $1.99 to $2.36.
Technical Outlook: Technically, OABI is in a strong uptrend. Immediate support is located at $1.90, while resistance sits at $2.13.
Market Sentiment: OABI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (77th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $7.33 (+274.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OABI is in a strong uptrend. Immediate support is located at $1.90, while resistance sits at $2.13.
Market Sentiment: OABI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Implied Volatility is high (77th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $7.33 (+274.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.99 -
$2.36
Company Quality Score
52/100
(HOLD)
Options IV Signal
77th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
45.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 77th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 274.1% below Wall St target ($7.33)
Trading Range Analysis
30-Day Trading Range
$1.99 -
$2.36
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$0.55
(27.5%)
Support & Resistance Levels
Support Level
$1.90
Resistance Level
$2.13
Current Trend
Strong Uptrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.08
Wall Street Target
$7.33
(+274.1%)
Revenue Growth (YoY)
247.3%
Profit Margin
-187.6%
Share & Embed Analysis
Last updated: August 04, 2026 4:11 PM ET
Data refreshes hourly during market hours. Next update: 5:11 PM
Data refreshes hourly during market hours. Next update: 5:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OABI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Charles S Berkman
SELL
7157 shares
2026-04-07
Kurt A Gustafson
SELL
6913 shares
2026-04-07
Matthew W Foehr
SELL
19244 shares
2026-04-07
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 55 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 53 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 51 HOLD |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$15 | 62 BUY |
